Published in PLoS One on January 10, 2013
Proteomics of Primary Hyperoxaluria Type 1 (PH1) | NCT03067142
An Empirical Biomarker-Based Calculator for Cystic Index in a Model of Autosomal Recessive Polycystic Kidney Disease-The Nieto-Narayan Formula. PLoS One (2016) 1.38
Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol (2014) 1.24
Identification of Biomarkers for PKD1 Using Urinary Exosomes. J Am Soc Nephrol (2014) 0.96
Molecular pathways and therapies in autosomal-dominant polycystic kidney disease. Physiology (Bethesda) (2015) 0.93
Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoS One (2013) 0.93
Size-exclusion chromatography-based enrichment of extracellular vesicles from urine samples. J Extracell Vesicles (2015) 0.91
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2015) 0.84
Urinary proteomics in chronic kidney disease: diagnosis and risk of progression beyond albuminuria. Clin Proteomics (2015) 0.81
The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat Rev Nephrol (2016) 0.78
Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol (2015) 0.77
Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD). Clin Exp Nephrol (2015) 0.76
Epigenetic silencing of the MUPCDH gene as a possible prognostic biomarker for cyst growth in ADPKD. Sci Rep (2015) 0.75
Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency? Int J Chron Obstruct Pulmon Dis (2017) 0.75
Quantitative mass spectrometry of urinary biomarkers. J Integr OMICS (2014) 0.75
Systems biology of polycystic kidney disease: a critical review. Wiley Interdiscip Rev Syst Biol Med (2015) 0.75
Potential urine proteomics biomarkers for primary nephrotic syndrome. Clin Proteomics (2017) 0.75
Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression. J Transl Med (2015) 0.75
Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics (2003) 16.60
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol (2008) 4.07
Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet (1999) 3.32
Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int (1992) 2.89
Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. Acta Med Scand Suppl (1957) 2.86
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int (2007) 2.64
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol (2006) 2.29
Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis (1983) 2.22
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int (2008) 1.84
Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol (2007) 1.83
Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol (2007) 1.77
Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int (2011) 1.64
Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (1994) 1.61
Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom (2004) 1.57
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med (2006) 1.52
Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol (1997) 1.52
Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2003) 1.46
Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol (2007) 1.42
Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics (2009) 1.41
Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes (2012) 1.38
The ADPKD genes pkd1a/b and pkd2 regulate extracellular matrix formation. Dis Model Mech (2010) 1.36
Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol (2007) 1.35
Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis (2006) 1.33
Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2010) 1.27
Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis (2005) 1.24
Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev (2009) 1.19
Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem (2012) 1.18
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.16
Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis (2010) 1.15
Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int (2009) 1.12
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One (2010) 1.12
Determinants of renal disease variability in ADPKD. Adv Chronic Kidney Dis (2010) 1.11
Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int (2010) 1.10
Gene profiling of polycystic kidneys. Nephrol Dial Transplant (2006) 1.09
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens (2010) 1.09
Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther (2009) 1.08
Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int (2001) 1.06
Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl (2011) 1.05
Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res (2009) 1.02
Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant (2009) 0.98
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem (2005) 0.90
Kidney injury molecule 1 (Kim1) is a novel ciliary molecule and interactor of polycystin 2. Biochem Biophys Res Commun (2007) 0.82
Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney Blood Press Res (2009) 0.79
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Polycystic kidney disease. Annu Rev Med (2009) 4.78
The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet (2002) 4.54
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med (2003) 3.78
Quality of care for children in commercial and Medicaid managed care. JAMA (2003) 3.60
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat Genet (2006) 3.19
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int (2009) 2.99
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol (2005) 2.92
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol (2007) 2.71
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet (2003) 2.55
Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int (2004) 2.55
Relationship between staff perceptions of hospital norms and hospital-level end-of-life treatment intensity. J Palliat Med (2007) 2.39
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J (2008) 2.38
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int (2003) 2.32
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol (2006) 2.29
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med (2011) 2.14
Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol (2009) 2.13
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant (2005) 2.09
Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest (2002) 2.07
Perceived discrimination in health care and health status in a racially diverse sample. Med Care (2008) 2.06
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res (2011) 2.06
Urine in clinical proteomics. Mol Cell Proteomics (2008) 2.05
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Total and intraabdominal fat distribution in preadolescents and adolescents: measurement with MR imaging. Radiology (2007) 1.92
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int (2008) 1.84
Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology (2003) 1.80
Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin. Cell (2004) 1.79
Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int (2010) 1.77
Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol (2007) 1.77
Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest (2012) 1.74
Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int (2004) 1.71
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int (2002) 1.66
Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol (2010) 1.65
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A (2008) 1.65
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Molecular diagnostics of Meckel-Gruber syndrome highlights phenotypic differences between MKS1 and MKS3. Hum Genet (2007) 1.64
Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol (2002) 1.63
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int (2005) 1.63
Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2010) 1.63
Differential renal function estimation using computerized tomography based renal parenchymal volume measurement. J Urol (2010) 1.62
Quantitative assessment of hepatic fibrosis in an animal model with magnetic resonance elastography. Magn Reson Med (2007) 1.61